Literature DB >> 15464426

X-linked adrenoleukodystrophy: role of very long-chain acyl-CoA synthetases.

Zhenzhen Jia1, Zhengtong Pei, Yuanyuan Li, Liumei Wei, Kirby D Smith, Paul A Watkins.   

Abstract

The principal biochemical abnormality in the neurodegenerative disorder X-linked adrenoleukodystrophy (X-ALD) is elevated plasma and tissue levels of very long-chain fatty acids (VLCFA). Enzymes with very long-chain acyl-CoA synthetase (VLACS) activity are required for VLCFA metabolism, including degradation by peroxisomal beta-oxidation or incorporation into complex lipids, and may also participate in VLCFA synthesis. Two enzymes with VLACS activity, ACSVL1 and BG1, were investigated for their potential role in X-ALD biochemical pathology. Skin fibroblast mRNA levels for ACSVL1, an enzyme previously shown to be in peroxisomes and to participate in VLCFA beta-oxidation, were not significantly different between normal controls, patients with childhood cerebral X-ALD, and patients with adrenomyeloneuropathy. Similar results were obtained with mRNA for BG1, a non-peroxisomal enzyme that is highly expressed in nervous system, adrenal gland, and testis, the principal tissues pathologically affected in X-ALD. No significant differences in the immunohistochemical staining patterns of tissues expressing either ACSVL1 or BG1 were observed when wild-type and X-ALD mice were compared. Western blot analysis of BG1 protein levels showed no differences between fibroblasts from controls, cerebral X-ALD, or adrenomyeloneuropathy patients. BG1 protein levels were similar in wild-type and X-ALD mouse brain, spinal cord, testis, and adrenal gland. We hypothesized that one function of BG1 was to direct VLCFA into the cholesterol ester synthesis pathway. However, BG1 depletion in Neuro2a cells using RNA interference did not decrease incorporation of labeled VLCFA into cholesterol esters. We conclude that the role, if any, of ACSVL1 and BG1 in X-ALD biochemical pathology is indirect.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15464426     DOI: 10.1016/j.ymgme.2004.06.015

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  7 in total

Review 1.  Peroxisomal acyl-CoA synthetases.

Authors:  Paul A Watkins; Jessica M Ellis
Journal:  Biochim Biophys Acta       Date:  2012-02-17

Review 2.  Role of fatty acid transport protein 4 in metabolic tissues: insights into obesity and fatty liver disease.

Authors:  Huili Li; Thomas Herrmann; Jessica Seeßle; Gerhard Liebisch; Uta Merle; Wolfgang Stremmel; Walee Chamulitrat
Journal:  Biosci Rep       Date:  2022-06-30       Impact factor: 3.976

3.  Fatty Acid Transport Proteins: Targeting FATP2 as a Gatekeeper Involved in the Transport of Exogenous Fatty Acids.

Authors:  Paul N Black; Constance Ahowesso; David Montefusco; Nipun Saini; Concetta C DiRusso
Journal:  Medchemcomm       Date:  2016-02-19       Impact factor: 3.597

4.  The Arabidopsis ALDP protein homologue COMATOSE is instrumental in peroxisomal acetate metabolism.

Authors:  Mark A Hooks; James E Turner; Elaine C Murphy; Katherine A Johnston; Sally Burr; Szymon Jarosławski
Journal:  Biochem J       Date:  2007-09-15       Impact factor: 3.857

5.  Baicalein 5,6,7-trimethyl ether activates peroxisomal but not mitochondrial fatty acid beta-oxidation.

Authors:  M Morita; M Kanai; S Mizuno; M Iwashima; T Hayashi; N Shimozawa; Y Suzuki; T Imanaka
Journal:  J Inherit Metab Dis       Date:  2008-05-09       Impact factor: 4.750

6.  PPAR- γ impairment alters peroxisome functionality in primary astrocyte cell cultures.

Authors:  Lorenzo Di Cesare Mannelli; Matteo Zanardelli; Laura Micheli; Carla Ghelardini
Journal:  Biomed Res Int       Date:  2014-03-04       Impact factor: 3.411

7.  Defining diagnostic cutoffs in neurological patients for serum very long chain fatty acids (VLCFA) in genetically confirmed X-Adrenoleukodystrophy.

Authors:  Tim W Rattay; Maren Rautenberg; Anne S Söhn; Holger Hengel; Andreas Traschütz; Benjamin Röben; Stefanie N Hayer; Rebecca Schüle; Sarah Wiethoff; Lena Zeltner; Tobias B Haack; Alexander Cegan; Ludger Schöls; Erwin Schleicher; Andreas Peter
Journal:  Sci Rep       Date:  2020-09-15       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.